Figure 1. The scene of the global launch of photonics biosensing technology and the forum on industry-university-research cooperation. Photographed by Hu Yongai

On August 19th, the "Hong Kong Innovation and Technology - Sharing with the World" - Global Launch of Photonic Quantum Biosensing Technology and Industry-University-Research Collaboration Forum was held at the Hong Kong Science Park Shenzhen Sub-Park in the Shenzhen Park of the Hetao Shenzhen-Hong Kong Technology Innovation Cooperation Zone.

At this forum, Wu Zhaopeng, CEO of Rafael Biotech (Shenzhen) Co., Ltd., officially unveiled the world's first optical quantum surface plasmon resonance biosensor. This breakthrough achievement, based on Quantum Plasmonic Lab-on-Chip (QPLoC) technology, embodies the efforts of the research and development team over more than two decades. It holds over 20 international patents and has received support from the Hong Kong government's Innovation and Technology Fund of 4 million.

Figure 2. Wu Zhaopeng, CEO of Rafael Biotech (Shenzhen) Co., Ltd., officially unveiled the world's first optical quantum surface plasmon resonance biosensor. Photographed by Hu Yongai

It is reported that this technology possesses three significant advantages. Firstly, it revolutionizes detection efficiency, enabling simultaneous detection of multiple pathogens without PCR amplification, and completing rapid screening for infectious diseases, tumor markers, etc. within 15 minutes. Secondly, it offers a notable cost advantage, with the patented design of the total internal reflection inverted prism significantly reducing the manufacturing cost of SPR sensors. Furthermore, its application prospects are vast, with potential widespread use in various medical fields such as brain glioma immune escape monitoring and early cancer screening. "Our technology will revolutionize traditional medical detection methods, making precision medicine more accessible," stated Wu Zhaopeng.

As a representative of Hong Kong enterprises stationed in the Shenzhen branch of the Hong Kong Science Park, Dr. Wu Zhaopeng, the founder of Rafael, shared his rapid development achieved through the collaboration between Shenzhen and Hong Kong. The Shenzhen branch of the Hong Kong Science Park provides full-chain support for stationed enterprises, namely "Hong Kong R&D + Shenzhen transformation". "Here, we can maintain Hong Kong's international scientific research advantages while conveniently connecting with mainland clinical trial resources, truly realizing the integration of 'the advantages of Hong Kong and Shenzhen'," Dr. Wu Zhaopeng emphasized.

Figure 3. As a representative of Hong Kong enterprises stationed in the Shenzhen branch of the Hong Kong Science Park, Rafael's founder, Wu Zhaopeng, shared his rapid development achieved through the collaboration between Shenzhen and Hong Kong. Photographed by Hu Yongai

The forum gathered experts and scholars from top institutions such as the Chinese University of Hong Kong, City University of Hong Kong, and ETH Zurich. Professor Ho Ho-Pui from the Chinese University of Hong Kong provided key optical design optimization solutions for SPR sensors, while Associate Professor Li Yongzhen from City University of Hong Kong verified the clinical value of this technology in brain tumor exosome detection. Zhang Jiajian, Senior Manager of Business Development at Hong Kong Science and Technology Parks Corporation, said at the event: "We will continue to provide comprehensive support for technology innovation enterprises and promote more Hong Kong scientific research achievements to the market."

Responsible editor: He Xuemo